Lumosa presents LT3001 at the stroke forum

Taiwan Stroke Society held its 2016 Annual Meeting and the inaugural “Asia Pacific Stroke Forum" (hereafter referred to as “the Forum”) on November 12 and 13 in The Grand Hotel, Taipei. Stroke specialists and key opinion leaders all over the world were invited to discuss the newest stroke treatment methods. Dr. Sheng-Wen Yeh of Lumosa Therapeutics (Lumosa, TPEx:6535) was invited to give an orally presentation on the findings in a recent non-primate study of LT3001, a novel chemical entity under development by Lumosa for the treatment of acute ischemic stroke.

Lumosa Presents LT3001 at the thrombolysis thrombectomy and acute stroke therapy symposium

Dr. Mimi Yeh of Lumosa Therapeutics (Lumosa) presented the recent advancement in the preclinical research of LT3001 in the oral session at the 13th International Symposium on Thrombolysis Thrombectomy and Acute Stroke Therapy (TTST), held in Kobe, Japan (October 30th and November 1, 2016).  TTST is one of the few international medical conferences focusing on stroke research. Lumosa was honored to be the only drug development company invited to present and the presentation titled “Study of a novel small molecule, LT3001, in a thromboembolic stroke model in non-human primates"

Lumosa is public traded on Taipei Exchange (6535.TWO)

Lumosa Therapeutics Co., Ltd., (Lumosa) is listed on the Emerging Stock Board in Taipei Exchange, Symbol 6535, on September 26, 2016. Lumosa is dedicated to new drug development for the treatment of CNS and inflammatory diseases using reSEARCH & DEVELOPMENT model. One of its pipeline, LT1001, is a week-long acting analgesic injection that is awaiting new drug approval from Taiwan FDA. The other, LT3001, is a novel treatment for acute ischemic stroke.

LT1001 clinical results accepted by the Clinical Journal of Pain

After successful execution of the license agreement with Syntano Technology Venture for China in June, Lumosa Therapeutics Co., Ltd. (TPEx 6535), receives a notification from “the Clinical Journal of Pain” (CJP) that the manuscript on LT1001 Phase III trial results was accepted for publication. “The Clinical Journal of Pain” is an esteemed international journal ranked among top 10 of clinical journals in analgesic and anesthetic field. It publishes many medical articles addressing pain management in clinical setting and new treatment models etc. for the past 30 years. The acceptance by CJP indicated LT1001 is regarded as an innovative product in clinical pain management, which deserves the recognition by international medical experts.

Lumosa recognized for its achievements at BioTaiwan

After successful licensing of LT1001 to Syntano Technology Venture, and approval for over-the-counter (OTC) listing (TPEx:6535) by the board of Taipei Exchange (TPEx), Lumosa was awarded the 2016 Biotech Potential Benchmark from the Bioindustry Association and Bronze Medal in the innovation category of 2016 Taipei Biotechnology Award from Taipei City Government. Dr. Wendy Huang, CEO of Lumosa Therapeutics, was also invited to give speeches in several conferences and seminars during the 2016 BioTaiwan event.

LT1001 out-licensed to China

Lumosa Therapeutics Co., Ltd. announced today the signing of an exclusive license agreement with Syntano Technology Venture - a Haike company (Syntano), granting Syntano the right to develop and commercialize its LT1001 product in China, Hong Kong and Macau.commercial successes with this product by our partners. Lumosa will continue to develop high potential new drugs, maximize the value of our pipeline assets and bring our shareholders the most returns”, said Dr. Tsai Chang-Hai, Chairman of Lumosa Company Board. Please click link for more information